Chair of Advisory Board
Dr Anthony (Tony) Magliocco is a Senior Member and Chair, Department of Anatomic Pathology at Moffitt Cancer Center as well as Executive Director of Esoteric Laboratory Services and the Morsani Molecular Diagnostic Laboratory, and Scientific Director of the Moffitt Tissue Core. He is Board Certified in anatomic pathology and completed a fellowship at the Fox Cancer Center and residency at the University of Calgary. Dr Magliocco has subspecialty expertise in breast, gynecological and molecular pathology and research interests in the areas of molecular predictive markers, digital analytical microscopy, and personalized medicine. He is also co-chair of pathology for the NRG cooperative clinical trials group, and was recently appointed to the NIH NCI Genitourinary Steering Committee.
Dr. Magliocco earned his M.D. at the University of Alberta, Edmonton, Canada. He completed an Anatomical Pathology Residency at the University of Calgary in the Department of Pathology at Foothills Hospital and Fellowships in Anatomical Pathology at Royal College of Physicians and Surgeons of Canada and College of American Pathologists FCAP Fellow. He completed a Post-Doctoral Fellowship in Molecular Surgical Pathology at Fox Chase Cancer Center.
In 1998, he joined the faculty at the University of Calgary, where he most recently served as Division Head of Pathology and Laboratory Medicine. He has also served as the Director of the Translational Laboratory at Tom Baker Cancer Centre and the Medical and Scientific Director of the Canadian Breast Cancer Foundation (CBCF)/Alberta Cancer Research Institute (ACRI) Biorepository in Calgary.
Dr. Magliocco has published over 100 peer-reviewed manuscripts and received numerous honors and awards including the Overall Academic Excellence Award at the University of Calgary; the Best Scientific Abstract Award at CARO; and the New Investigator Award from the Alberta Cancer Board. Dr. Magliocco has been continuously funded over the course of the past ten years through peer reviewed grants from the National Cancer Institute of Canada (NCIC) and the Alberta Cancer Board.
Dr. Magliocco’s clinical interest is in the development of novel molecular testing for integration into routine clinical service. His research focuses on understanding the molecular basis of cancer progression including the mechanisms of metastasis and development of resistance to therapeutics including the basis of radiotherapy resistance with a major focus on women’s cancers.